WASHINGTON, Oct. 09, 2022 (GLOBE NEWSWIRE) -- Global 3D bioprinting market was valued at USD 1.5 Billion in 2021 and is projected to attain a value of USD 3.7 Billion by 2028 during the forecast period, 20222028.
Get Sample Copy of This Report: https://www.vantagemarketresearch.com/3d-bioprinting-market-1235/request-sample
As the demand for bioprinting continues to increase, so too does the need for 3D bioprinting. 3D bioprinting market uses small droplets of cell-containing material to create 3D objects in vitro It is useful for creating organs, tissues, and other structures from stem cells or other cells. It is also useful for creating customized implants and drugs.
The growing demand for 3D bioprinting has led to the development of new technologies and processes that make it easier and faster to create 3D objects. As the technology opens up new opportunities for the development of novel medical treatments, 3D bioprinting market growth is being driven by the increasing demand for personalized medicine, as well as the increasing need for customized structures and therapies. With each passing year, the technology is also becoming more affordable and accessible, making it an attractive option for clinical applications. This growth in demand will likely continue to accelerate in the future, as further advances in technology are made.
Top Players in Global 3D Bioprinting Market
Bioprinting is booming as a technology for creating tissue and organ replacement parts. The following are three factors driving demand for this innovative technology:
1. Growing aging population: The worlds population is growing older, which means there will be an increasing need for tissue and organ replacements. Bioprinting can help to fill this need by creating replacement tissues and organs from patient-specific cells. Over 1 billion people are above 60 years old and the number is projected to expand to 1.4 billion by 2050.
2. Declining supplies of natural organs and tissues: The availability of natural organs and tissues for transplantation is dwindling in worldwide 3D bioprinting market due to the increasing incidence of diseases such as Alzheimers, heart failure, and cancer. By using bioprinting, hospitals can create replacement tissues or organs specifically tailored to the needs of individual patients.
3. Progress in regenerative medicine: Regenerative medicine utilizes techniques such as cell therapy and 3D printing to restore function to damaged or diseased tissue. By printing tissue components in a controlled environment, regenerative medicine providers are able to engineers complex tissue constructs that would otherwise be extremely difficult or impossible to achieve.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.vantagemarketresearch.com/buy-now/3d-bioprinting-market-1235/0
Key Findings:
Scope of the Report:
Increasing Adoption of 3D Bioprinting for Engineering Organs
3D bioprinting market is becoming an increasingly important as it enables the rapid, low-cost fabrication of complex components and structures from a variety of biocompatible materials. Vantage Market Research estimates that global spending on 3D printing services will top $2.3 billion by 2025, with growth rates well above the average for all software categories over the same period.
3D bioprinting market currently has niche applications in large-scale industrial production, but its potential to create low-cost human tissues and organs has drawn considerable interest. This is due in part to the high degree of customization that is possible with 3D bioprinting, which can enable precise control over tissue properties, including shape, size, and composition.
Every year, more than 10,000 Americans are put on waiting list for organ transplantation and over 6,000 of them die due to shortage or inability to get the suitable donor. This represents a huge opportunity for the players active in the global 3D bioprinting market to incentivize this revenue opportunity by engineering organ at scale to meet the demand and supply gap.
In fact, bioprinting is an emerging technology that enables the printing of nearly any type of biological tissue and organ. This technology has already been used to create structures such as heart valves, skin patches, and bone implants. However, there are still many applications for bioprinting that have yet to be explored.
3D printing is revolutionizing the way products are designed, and it is now being used to create organs at scale. By printing organs in a customized manner, we can improve the accuracy, predictability, and efficiency of organ printing.
There are many different types of organs that could benefit from bioprinting. Examples of organs that could be printed using this technology include lungs, liver, kidneys, and hearts. With bioprinting, surgeons could potentially print new organs onsite if they become damaged or diseased.
The applications for 3D bioprinting market are endless, and we are just starting to scratch the surface of what this technology can do. We believe that bioprinting will play a major role in engineering organ at scale in the future.
Download Full Report (176 Pages PDF with Insights, Charts, Tables, Figures) at@ https://www.vantagemarketresearch.com/industry-report/3d-bioprinting-market-1235
As per Vantage Market Research, end-users and scientist have started paying attention to making use of 3D bioprinting on large scale thanks to numerous benefits of using 3D bioprinting for organ engineering. Some of the most important benefits include:
Browse market data Tables and Figures spread through 176 Pages and in-depth TOC on "3d Bioprinting Market by Technology (Inkjet-based, Magnetic Levitation, Syringe-based, Laser-based), by Application (Medical, Dental, Biosensors, Consumer/Personal Product Testing), by Region (North America, Latin America, Europe, Asia Pacific) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".
Inkjet Technology Generates More than 38% Revenue of Bioprinting Market
3D bioprinting market is becoming popular due to its versatility and ability to create complex tissue structures. However, one disadvantage of 3D bioprinting is the need for magnetic levitation technology in order to print large objects. Inkjet technology is becoming more popular for 3D bioprinting due to its lower printing costs and the ability to print larger objects. Inject technology uses a syringe filled with liquid bioprinters to create realistic tissue constructs.
Some of the biggest advantages of inkjet technology in the global 3D bioprinting market include its low cost and the ability to print complex tissue constructs. Inkjet printers can also produce large quantities of tissue at once, which makes them ideal for medical applications. Deploying inject printers in hospitals could improve the quality of patient care by allowing for faster production of customized tissue constructs. In addition, inject printers could help to reduce the cost of healthcare by reducing the need for magnetic levitation technology.
As per Vantage Market Research, most of the users in the global 3D bioprinting market prefer inkjet bioprinting technology because the printing can be faster and more accurate than magnetic levitation printing. Second, inkjet printing does not require the use of a cold bed or vacuum chamber both of which can be time-consuming and expensive to set up. Third, inkjet printing is less likely to produce errors due to materials incompatibility than magnetic levitation printing. Inkjet printing is also better at reproducing delicate features and patterns than magnetic levitation printing.
Overall, inkjet technology is becoming more popular for 3D bioprinting due to its speed, accuracy, and versatility.
Key Questions Answered in The Report:
Customization of the Report:
The report can be customized as per client needs or requirements. For any queries, you can contact us on sales@vantagemarketresearch.com or +1 (202) 380-9727. Our sales executives will be happy to understand your needs and provide you with the most suitable reports.
Browse More Related Report:
About Vantage Market Research:
We, at Vantage Market Research, provide quantified B2B high quality research on more than 20,000 emerging markets, in turn, helping our clients map out constellation of opportunities for their businesses. We, as a competitive intelligence market research and consulting firm provide end to end solutions to our client enterprises to meet their crucial business objectives. Our clientele base spans across 70% of Global Fortune 500 companies. The company provides high quality data and market research reports. The company serves various enterprises and clients in a wide variety of industries. The company offers detailed reports on multiple industries including Chemical Materials and Energy, Food and Beverages, Healthcare Technology, etc. The companys experienced team of Analysts, Researchers, and Consultants use proprietary data sources and numerous statistical tools and techniques to gather and analyse information.
Follow Us on LinkedIn: https://www.linkedin.com/company/vantage-market-research/
Follow Us on Twitter: https://twitter.com/vantagemarketr
Follow Us on Facebook: https://www.facebook.com/vantagemarketresearch
Contact us
Eric Kunz
6218 Georgia Avenue NW Ste 1 - 564
Washington DC 20011-5125
United States Tel: +1 202 380 9727
Email: sales@vantagemarketresearch.com
Website: https://www.vantagemarketresearch.com/
Latest Vantage Market Research Press Releases @https://www.vantagemarketresearch.com/insight/press-releases
Latest Vantage Market Research Blog @ https://www.vantagemarketresearch.com/insight/blogs
Blog:
- Stem cells for a Webby! [Last Updated On: April 28th, 2010] [Originally Added On: April 28th, 2010]
- Stem cells for a Webby! [Last Updated On: April 28th, 2010] [Originally Added On: April 28th, 2010]
- Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: April 30th, 2010] [Originally Added On: April 30th, 2010]
- Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: April 30th, 2010] [Originally Added On: April 30th, 2010]
- Google to Invest in Regenerative Medicine [Last Updated On: May 5th, 2010] [Originally Added On: May 5th, 2010]
- Biotech tax credit appears perfectly designed for cell therapy companies to recoup research dollars spent in 2009-10 [Last Updated On: May 22nd, 2010] [Originally Added On: May 22nd, 2010]
- The changing face of PR and why it matters to regenmed [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- The changing face of PR and why it matters to regenmed [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- FDA files injunction again Regenerative Sciences citing Regenexx violates regulations [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- FDA files injunction again Regenerative Sciences citing Regenexx violates regulations [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- Careers in cell therapy & regenerative medicine [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- Careers in cell therapy & regenerative medicine [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- The LinkedIn Cell Therapy Industry Group - 1,000 members strong [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- Cell Therapies: Commercializing a New Class of Biopharmaceuticals [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- The LinkedIn Cell Therapy Industry Group - 1,000 members strong [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- Cell Therapies: Commercializing a New Class of Biopharmaceuticals [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- Hydra VII - The European Summer School on Stem Cells and Regenerative Medicine [Last Updated On: April 6th, 2011] [Originally Added On: April 6th, 2011]
- Alan Russell: Why can't we grow new body parts? [Last Updated On: May 23rd, 2011] [Originally Added On: May 23rd, 2011]
- Preserving Stem Cells: Regenerative Medicine [Last Updated On: June 7th, 2011] [Originally Added On: June 7th, 2011]
- Disease in a Dish: Using Stem Cells to Model Huntington's Disease and Spinal Muscular Atrophy [Last Updated On: June 8th, 2011] [Originally Added On: June 8th, 2011]
- Spotlight on Cancer Stem Cell Research [Last Updated On: June 21st, 2011] [Originally Added On: June 21st, 2011]
- In vivo cell trafficking just took a leap forward [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- In vivo cell trafficking just took a leap forward [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- A Dose of Reality on Alternative Stem Cell Treatments: What you don't know can hurt you [Last Updated On: July 7th, 2011] [Originally Added On: July 7th, 2011]
- Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: July 10th, 2011] [Originally Added On: July 10th, 2011]
- Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: July 10th, 2011] [Originally Added On: July 10th, 2011]
- Opening Remarks, Screening Stem Cells 2009: From Reprogramming to Regenerative Medicine [Last Updated On: July 22nd, 2011] [Originally Added On: July 22nd, 2011]
- Clinical trial costs [Last Updated On: July 31st, 2011] [Originally Added On: July 31st, 2011]
- Clinical trial costs [Last Updated On: July 31st, 2011] [Originally Added On: July 31st, 2011]
- A New Era in Regenerative Medicine [Last Updated On: August 1st, 2011] [Originally Added On: August 1st, 2011]
- Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. [Last Updated On: August 14th, 2011] [Originally Added On: August 14th, 2011]
- Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. [Last Updated On: August 14th, 2011] [Originally Added On: August 14th, 2011]
- You and Your Heath TV Show - Orthopedic Regenerative Medicine Part 1 [Last Updated On: August 16th, 2011] [Originally Added On: August 16th, 2011]
- The Future of Stem Cells and Regenerative Medicine [Last Updated On: August 19th, 2011] [Originally Added On: August 19th, 2011]
- Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- Commercial-stage Cell Therapy Companies and Products [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- Commercial-stage Cell Therapy Companies and Products [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Laurel Barchas: The World Stem Cell Summit brings people together to find therapies [Last Updated On: October 9th, 2011] [Originally Added On: October 9th, 2011]
- Regenerative Medicine - Video [Last Updated On: October 13th, 2011] [Originally Added On: October 13th, 2011]
- Commercializing Cell-based Regenerative Medicines [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- Commercializing Cell-based Regenerative Medicines [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- C2CAM - 2011.11.15 - Regenerative Medicine - Dulce Base - Video [Last Updated On: November 18th, 2011] [Originally Added On: November 18th, 2011]
- Dr. Craig Saunders Discusses Stem Cells and Regenerative Medicine at the Evolution of Fat Workshop - Video [Last Updated On: November 25th, 2011] [Originally Added On: November 25th, 2011]
- Sabrina Cohen Foundation Thanks Stem Cell Researchers [Last Updated On: November 27th, 2011] [Originally Added On: November 27th, 2011]
- Sabrina Cohen Foundation Thanks Stem Cell Researchers [Last Updated On: November 27th, 2011] [Originally Added On: November 27th, 2011]
- Medical tourism in Croatia - Regenerative medicine-Stem cells in reconstructive surgery - Video [Last Updated On: November 28th, 2011] [Originally Added On: November 28th, 2011]
- "You and Your Health" TV Show - Orthopedic Regenerative Medicine - Video [Last Updated On: November 28th, 2011] [Originally Added On: November 28th, 2011]
- Dr. Craig Saunders Discusses Stem Cells and Regenerative Medicine at the Evolution of Fat Workshop - Video [Last Updated On: November 28th, 2011] [Originally Added On: November 28th, 2011]
- The Future of Stem Cells and Regenerative Medicine - Video [Last Updated On: November 28th, 2011] [Originally Added On: November 28th, 2011]
- A New Era in Regenerative Medicine - Video [Last Updated On: November 29th, 2011] [Originally Added On: November 29th, 2011]
- What is Regenerative Medicine? | Los Angeles | Hollywood | Beverly Hills - Video [Last Updated On: November 29th, 2011] [Originally Added On: November 29th, 2011]
- You and Your Heath TV Show - Orthopedic Regenerative Medicine Part 1 - Video [Last Updated On: November 29th, 2011] [Originally Added On: November 29th, 2011]
- Dr Farshchian: Regenerative Medicine shows Potentials - Video [Last Updated On: December 1st, 2011] [Originally Added On: December 1st, 2011]
- An amazing story of stem cells, regenerative medicine and healing power: - Video [Last Updated On: December 1st, 2011] [Originally Added On: December 1st, 2011]
- TEDxPhoenix - Jane Maienschein - Stem Cells, Regenerative Medicine and Us - Video [Last Updated On: December 2nd, 2011] [Originally Added On: December 2nd, 2011]
- Retroviruses, Reproduction, and Regenerative Medicine: The Influence of Federal Funding - Video [Last Updated On: December 2nd, 2011] [Originally Added On: December 2nd, 2011]
- McEwen Centre for Regenerative Medicine - Video [Last Updated On: December 2nd, 2011] [Originally Added On: December 2nd, 2011]
- Mayo Clinic Regenerative Medicine Consult Service - Video [Last Updated On: December 3rd, 2011] [Originally Added On: December 3rd, 2011]
- 4th International Symposium on Regenerative Medicine, Tissue and Genetic Engineering - Video [Last Updated On: December 8th, 2011] [Originally Added On: December 8th, 2011]
- StemCellTV Talks to Elona Baum of the California Institute of Regenerative Medicine - Video [Last Updated On: December 10th, 2011] [Originally Added On: December 10th, 2011]
- StemCellTV Talks to Morrie Ruffin of Alliance for Regenerative Medicine at Meeting on the Mesa - Video [Last Updated On: December 10th, 2011] [Originally Added On: December 10th, 2011]
- StemCellTV Talks to Elona Baum of the California Institute of Regenerative Medicine - Video [Last Updated On: December 10th, 2011] [Originally Added On: December 10th, 2011]
- StemCellTV Talks to Morrie Ruffin of Alliance for Regenerative Medicine at Meeting on the Mesa - Video [Last Updated On: December 10th, 2011] [Originally Added On: December 10th, 2011]
- Active phase III or II/III cell therapy trials [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- Active phase III or II/III cell therapy trials [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- 2011 Summit: Harnessing Regenerative Medicine for US Service-members, Major General James K. Gilman - Video [Last Updated On: December 14th, 2011] [Originally Added On: December 14th, 2011]
- Inactive and recently failed or terminated phase III or II/III cell therapy trials [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Recently approved cell therapy products [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Recently approved cell therapy products [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Inactive and recently failed or terminated phase III or II/III cell therapy trials [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Stem Cell Clinical Trial for Heart Failure: Eduardo Marban - CIRM Spotlight on Disease - Video [Last Updated On: December 22nd, 2011] [Originally Added On: December 22nd, 2011]
- Stem Cell Clinical Trial for Heart Failure: Eduardo Marban - CIRM Spotlight on Disease - Video [Last Updated On: December 22nd, 2011] [Originally Added On: December 22nd, 2011]
- Coast To Coast AM: 15.11.2011 - Regenerative Medicine/ Dulce Base - Video [Last Updated On: December 24th, 2011] [Originally Added On: December 24th, 2011]
- Coast To Coast AM: 15.11.2011 - Regenerative Medicine/ Dulce Base - Video [Last Updated On: December 25th, 2011] [Originally Added On: December 25th, 2011]
- 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? [Last Updated On: January 1st, 2012] [Originally Added On: January 1st, 2012]
- 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? [Last Updated On: January 1st, 2012] [Originally Added On: January 1st, 2012]
- ACT Announces Aberdeen Royal Infirmary in Scotland as Additional Site for Phase 1/2 Clinical Trial Using hESC-Derived ... [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]